US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
TWI238824B
(en)
|
2001-05-14 |
2005-09-01 |
Novartis Ag |
4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
|
JP4636486B2
(en)
*
|
2002-02-11 |
2011-02-23 |
バイエル、ファーマシューテイカルズ、コーポレイション |
Arylurea with angiogenesis inhibitory activity
|
US20030199525A1
(en)
*
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
CA2494421A1
(en)
|
2002-08-06 |
2004-02-12 |
Astrazeneca Ab |
Condensed pyridines and pyrimidines with tie2 (tek) activity
|
DE60323133D1
(en)
|
2002-12-13 |
2008-10-02 |
Smithkline Beecham Corp |
CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS
|
UA80171C2
(en)
|
2002-12-19 |
2007-08-27 |
Pfizer Prod Inc |
Pyrrolopyrimidine derivatives
|
AR045037A1
(en)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
|
US7312215B2
(en)
|
2003-07-29 |
2007-12-25 |
Bristol-Myers Squibb Company |
Benzimidazole C-2 heterocycles as kinase inhibitors
|
TW200530238A
(en)
*
|
2003-10-15 |
2005-09-16 |
Osi Pharm Inc |
Imidazopyrazine tyrosine kinase inhibitors
|
GB0401334D0
(en)
*
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
JP2007520559A
(en)
*
|
2004-02-03 |
2007-07-26 |
アボット・ラボラトリーズ |
Aminobenzoxazoles as therapeutic agents
|
ATE433979T1
(en)
|
2004-04-02 |
2009-07-15 |
Osi Pharm Inc |
HETEROBICYCLIC PROTEIN KINASE INHIBITORS SUBSTITUTED WITH A 6,6-BICYCLIC RING
|
US7550499B2
(en)
|
2004-05-12 |
2009-06-23 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
WO2005116035A1
(en)
*
|
2004-05-27 |
2005-12-08 |
Pfizer Products Inc. |
Pyrrolopyrimidine derivatives useful in cancer treatment
|
MY139689A
(en)
*
|
2004-07-20 |
2009-10-30 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
AR050365A1
(en)
|
2004-08-02 |
2006-10-18 |
Osi Pharm Inc |
INHIBITING COMPOUNDS OF ARIL-AMINO PIRROLOPIRIMIDINE PULROLOPIRIMIDINE REPLACED
|
ATE499370T1
(en)
|
2005-01-19 |
2011-03-15 |
Bristol Myers Squibb Co |
2-PHENOXY-N-(1,3,4-THIADIZOL-2-YL)PYRIDINE-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES
|
US7714002B2
(en)
|
2005-06-27 |
2010-05-11 |
Bristol-Myers Squibb Company |
Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
US7700620B2
(en)
|
2005-06-27 |
2010-04-20 |
Bristol-Myers Squibb Company |
C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
EP1896466B1
(en)
|
2005-06-27 |
2011-04-13 |
Bristol-Myers Squibb Company |
N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
EP1896417B1
(en)
|
2005-06-27 |
2011-03-23 |
Bristol-Myers Squibb Company |
Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
US7566721B2
(en)
|
2005-08-08 |
2009-07-28 |
Osi Pharmaceuticals, Inc. |
Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
|
ES2374450T3
(en)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
ANTI-BANGEOUS RESPONSE BIOLOGICAL MARKERS FOR KINNER INHIBITORS OF THE GROWTH FACTOR RECEIVER 1 SIMILAR TO INSULIN.
|
AR057960A1
(en)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
BICYCLE PROTEIN QUINASE INHIBITORS
|
US8575164B2
(en)
|
2005-12-19 |
2013-11-05 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy
|
US7960569B2
(en)
|
2006-10-17 |
2011-06-14 |
Bristol-Myers Squibb Company |
Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
WO2008064157A1
(en)
|
2006-11-22 |
2008-05-29 |
Incyte Corporation |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
NZ586642A
(en)
|
2008-01-11 |
2012-04-27 |
Natco Pharma Ltd |
Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
|
EP2283020B8
(en)
|
2008-05-19 |
2012-12-12 |
OSI Pharmaceuticals, LLC |
Substituted imidazopyr-and imidazotri-azines
|
ES2570429T3
(en)
*
|
2008-10-16 |
2016-05-18 |
Univ California |
Condensed Ring Heteroaryl Kinase Inhibitors
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010123792A1
(en)
|
2009-04-20 |
2010-10-28 |
Osi Pharmaceuticals, Inc. |
Preparation of c-pyrazine-methylamines
|
IN2012DN02139A
(en)
*
|
2009-09-10 |
2015-08-07 |
Novartis Ag |
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
AU2011223655A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
JP2013522215A
(en)
|
2010-03-09 |
2013-06-13 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Combined anticancer therapy
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
BR112013025792A2
(en)
*
|
2011-04-05 |
2018-04-24 |
Pfizer Ltd |
PYRROID-RELATED KINASE INHIBITORS [2,3-D] PYRIMIDINE TROPOMISINE
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
EA025496B1
(en)
|
2011-05-17 |
2016-12-30 |
Принсипиа Биофарма Инк. |
Tyrosine kinase inhibitors
|
EA201490265A1
(en)
|
2011-07-13 |
2014-12-30 |
Фармасайкликс, Инк. |
BLUTON TYROSINKINASE INHIBITORS
|
EP2751112B1
(en)
|
2011-09-02 |
2019-10-09 |
The Regents of The University of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
PT2892900T
(en)
|
2012-09-10 |
2017-11-06 |
Principia Biopharma Inc |
Pyrazolopyrimidine compounds as kinase inhibitors
|
CN104995192A
(en)
|
2012-09-26 |
2015-10-21 |
加利福尼亚大学董事会 |
Modulation of IRE1
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
EP3816155A1
(en)
*
|
2013-08-23 |
2021-05-05 |
Virginia Commonwealth University |
Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease
|
TN2016000094A1
(en)
|
2013-09-30 |
2017-07-05 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase.
|
JP6493218B2
(en)
*
|
2013-11-08 |
2019-04-03 |
小野薬品工業株式会社 |
Pyrrolopyrimidine derivatives
|
CA2834528A1
(en)
*
|
2013-11-26 |
2015-05-26 |
Pharmascience Inc. |
Protein kinase inhibitors
|
CA2934989C
(en)
|
2014-02-03 |
2017-08-08 |
Cadila Healthcare Limited |
Novel heterocyclic compounds
|
WO2015127310A1
(en)
|
2014-02-21 |
2015-08-27 |
Principia Biopharma Inc. |
Salts and solid form of a btk inhibitor
|
AU2015364335B2
(en)
|
2014-12-18 |
2020-11-26 |
Principia Biopharma Inc. |
Treatment of pemphigus
|
TW201718572A
(en)
|
2015-06-24 |
2017-06-01 |
普林斯匹亞生物製藥公司 |
Tyrosine kinase inhibitors
|
AU2016322063A1
(en)
*
|
2015-09-16 |
2018-04-12 |
Loxo Oncology, Inc. |
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
JP7011596B2
(en)
*
|
2015-12-02 |
2022-02-10 |
アストライア セラピューティクス, エルエルシー |
Piperidinyl nociceptin receptor compound
|
CN107513068A
(en)
*
|
2016-06-16 |
2017-12-26 |
中国科学院上海药物研究所 |
A kind of new compound and its preparation and application with FGFR inhibitory activity
|
KR102391693B1
(en)
|
2016-06-29 |
2022-04-29 |
프린시피아 바이오파마, 인코퍼레이티드 |
2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl] Modified release formulation of -4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-ennitrile
|
KR20210057014A
(en)
*
|
2018-09-13 |
2021-05-20 |
깃세이 야쿠힌 고교 가부시키가이샤 |
Imidazopyridinone compound
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
KR20230121758A
(en)
|
2020-11-18 |
2023-08-21 |
데시페라 파마슈티칼스, 엘엘씨. |
GCN2 and PERK kinase inhibitors and methods of use thereof
|